NCT06994299 2025-11-18
PRISM
Weill Medical College of Cornell University
Phase 2 Withdrawn
Clinical Trials
41 trialsNCT06361758 2025-05-23
Second-line Treatment With CAdonilimab and LEnvatinib for Unresectable HCC
Shanghai Zhongshan Hospital
Phase 2 Withdrawn
NCT02939807 2025-04-27
A Phase II Study of ABC294640 as Monotherapy in Patients With Advanced Hepatocellular Carcinoma
Medical University of South Carolina
Phase 2 Withdrawn
NCT04791228 2025-01-01
A Pilot Study of Thermodox and MR-HIFU for Treatment of Relapsed Solid Tumors
Children's National Research Institute
Phase 2 Withdrawn
NCT00756782 2024-09-04
A Study of TAC-101 in Combination With TACE Versus TACE Alone in Asian Patients With Advanced Hepatocellular Carcinoma
Taiho Oncology, Inc.
Phase 2 Withdrawn
NCT03722498 2023-07-11
Phase â…¡ Study of HAIC of FOLFOX vs. Sorafenib in HCC Refractory to TACE
Sun Yat-sen University
Phase 2 Withdrawn
NCT05886257 2023-06-02
Candonilimab Plus Bevacizumab for Patients With Advanced HCC Who Progressed on A+T
Sun Yat-sen University
Phase 2 Withdrawn
NCT05039736 2023-05-12
A Phase II Study to Evaluate the Effects of Sequential Therapy With the Anti c-MET/VEGFR Tyrosine Kinase Inhibitor (TKI), Cabozantinib, Followed by an Anti-PD-1 Antibody (Nivolumab) in Patients With Advanced HCC Who Progressed on First-line Therapy
M.D. Anderson Cancer Center
Phase 2 Withdrawn
NCT05157451 2023-03-23
Y-90 Versus SBRT for Inoperable HCC
OHSU Knight Cancer Institute
Phase 2 Withdrawn
NCT04178642 2022-12-14
LIDA-ADJ
University Hospital, Montpellier
Phase 2 Withdrawn
NCT05327738 2022-12-14
Yttrium Y 90 Glass Microspheres, Atezolizumab, and Cabozantinib for the Treatment of Unresectable or Locally Advanced Hepatocellular Carcinoma
OHSU Knight Cancer Institute
Phase 2 Withdrawn
NCT03908255 2022-01-28
BCAA in HCC
Louisiana State University Health Sciences Center in New Orleans
Phase 2 Withdrawn
NCT04947371 2021-07-01
Adjuvant Therapy With Anlotinib for HCC
Shanghai Zhongshan Hospital
Phase 2 Withdrawn
NCT04526080 2021-02-26
TheraBionics
Wake Forest University Health Sciences
Phase 2 Withdrawn
NCT02129322 2021-02-15
Effect of Adjuvant Therapy by Sorafenib, Oxaliplatin and S-1
Zhejiang University
Phase 2 Withdrawn
NCT00020774 2020-07-31
SCH 66336 With or Without Gemcitabine Followed by Surgery Compared With Surgery Alone in Treating Patients With Primary Liver Cancer
Jonsson Comprehensive Cancer Center
Phase 2 Withdrawn
NCT04025567 2020-03-16
Vancomycin in Patients With Unresectable Fibrolamellar Hepatocellular Carcinoma (FLC) Oral
National Institutes of Health Clinical Center (CC)
Phase 2 Withdrawn
NCT02580253 2020-02-17
Adjuvant Chemotherapy Based on the Adenosine Triphosphate Tumor Chemosensitivity Assay for Hepatocellular Carcinoma After Liver Transplantation
Zhejiang University
Phase 2 Withdrawn
NCT02289300 2020-01-13
A Study to Evaluate a Study Drug, DCB-BO1202, for Alleviating Liver Fibrosis in Liver Cancer Patients
A2 Healthcare Taiwan Corporation
Phase 2 Withdrawn
NCT02946138 2019-09-09
Phase II Trial of Carbon-ion Radiotherapy Combined With GM-CSF for the Treatment of Hepatocellular Carcinoma
Shanghai Proton and Heavy Ion Center
Phase 2 Withdrawn
NCT03919383 2019-06-03
Phase II of Lenvatinib Plus Toripalimab for Advanced HCC
Sun Yat-sen University
Phase 2 Withdrawn
NCT03775707 2019-05-06
Lenvatinib Plus PD-1 Antibody for Intermediate-stage HCC Beyond Up-to-seven Criteria
Sun Yat-sen University
Phase 2 Withdrawn
NCT03780634 2019-05-06
HAIC Plus PD-1 Antibody vs HAIC Plus Sorafenib for Advanced HCC
Sun Yat-sen University
Phase 2 Withdrawn
NCT03803254 2019-05-06
HAIC Plus Lenvatinib and PD-1 Antibody Versus HAIC Plus Lenvatinib for Advanced HCC
Sun Yat-sen University
Phase 2 Withdrawn
NCT03782831 2019-05-02
TACE Plus PD-1 Antibody vs TACE Alone for Unresectable HCC
Sun Yat-sen University
Phase 2 Withdrawn
NCT03746249 2019-04-17
Phase II of Lenvatinib Plus PD-1 Antibody for Advanced HCC
Sun Yat-sen University
Phase 2 Withdrawn
NCT02702960 2018-06-15
Sequential, Related Donor Partial Liver Transplantation Followed by Bone Marrow Transplantation for Hepatocellular Carcinoma (HCC)
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Withdrawn
NCT02908165 2018-01-10
Randomized Phase II Trial of Chemoembolization and Sorafenib
Yale University
Phase 2 Withdrawn
NCT02406508 2017-12-18
Sequential Melphalan for Use With Hepatic Delivery System Treatment Followed by Sorafenib in Patients With Unresectable HCC
Delcath Systems Inc.
Phase 2 Withdrawn
NCT00039078 2017-06-26
Radiolabeled Glass Beads (TheraSphere®) in Treating Patients With Primary Liver Cancer That Cannot Be Removed by Surgery
University of Pittsburgh
Phase 2 Withdrawn
NCT01953406 2016-04-27
The Efficacy of 5-fluorouracil/Mitomycin for the Patients With Pulmonary Metastasis of Hepatocellular Carcinoma
Seoul National University Hospital
Phase 2 Withdrawn
NCT01775280 2015-06-09
RESRAD
University of Zurich
Phase 2 Withdrawn
NCT02070419 2014-12-02
TACE With or Without Radiation Therapy in Treating Patients With Stage A-C Liver Cancer
Case Comprehensive Cancer Center
Phase 2 Withdrawn
NCT00808145 2014-10-22
Study of Sorafenib, Gemcitabine, and Cisplatin in Advanced Hepatocellular Carcinoma (HCC)
Lahey Clinic
Phase 2 Withdrawn
NCT01859182 2014-09-09
Selumetinib and Akt Inhibitor MK-2206 in Treating Patients With Refractory or Advanced Gallbladder or Bile Duct Cancer That Cannot Be Removed By Surgery
National Cancer Institute (NCI)
Phase 2 Withdrawn
NCT01722175 2014-07-22
ALPPS
Washington University School of Medicine
Phase 2 Withdrawn
NCT01669668 2014-07-16
Radiofrequency Ablation in Treating Patients With Liver Cancer (Hepatocellular Carcinoma)
Washington University School of Medicine
Phase 2 Withdrawn
NCT01432314 2014-06-26
RTANDTACE
Asan Medical Center
Phase 2 Withdrawn
NCT00493428 2014-05-16
Treatment of Non-Metastatic Hepatocellular Carcinoma in Humans by Increasing Gabaergic Activity: A Pilot Study
University of Manitoba
Phase 2 Withdrawn
NCT01194206 2012-04-18
Stereotactic Body Radiation Therapy in Liver Cancer That Cannot be Removed by Surgery or Transplant
Case Comprehensive Cancer Center
Phase 2 Withdrawn
NCT00003714 2012-02-22
Chemotherapy in Treating Patients With Unresectable Primary or Metastatic Kidney Cancer
M.D. Anderson Cancer Center
Phase 2 Withdrawn